The study evaluates whether implementing a wireless monitoring system for patients admitted to hospital wards reduces mortality and cardiopulmonary failure.

开始日期2024-11-01

申办/合作机构

北京九棵树国际医药技术研究中心大庆分中心

NCT06404996 / Not yet recruitingN/AIIT

Smart-phone Application Versus Conventional Paper for the Documentation of Voiding Dysfunction in Children: Which Diary is Most Advantageous

The objective of the research is to compare the written voiding diary method to the smart-phone diary, DryDawn®, which the investigators selected among several applications using specific criteria appropriate to our population. The investigators aim is to describe the method that proves to be most efficient by assessing which diary provides the best quality and amount of information, and draws the highest level of satisfaction from participants.
Patient satisfaction will be assessed using a questionnaire that was designed for use in this study.

开始日期2024-08-01

申办/合作机构

北京九棵树国际医药技术研究中心大庆分中心

NCT05112705 / RecruitingN/AIIT

Diagnosing Deep-vein Thrombosis Early in Critically Ill Patients (DETECT) Trial

The DETECT randomized controlled trial addresses the question of whether surveillance ultrasound in critically ill patients by facilitating DVT detection reduces the incidence of PE and lowers all-cause 90-day mortality. The primary outcome is 90-day all-cause mortality.

开始日期2023-03-21

申办/合作机构

北京九棵树国际医药技术研究中心大庆分中心

100 项与北京九棵树国际医药技术研究中心大庆分中心相关的临床结果

登录后查看更多信息

0 项与北京九棵树国际医药技术研究中心大庆分中心相关的专利（医药）

登录后查看更多信息

2,414

项与北京九棵树国际医药技术研究中心大庆分中心相关的文献（医药）

2025-01-01·Annals of Hepatology

Knowledge about metabolic dysfunction-associated steatotic liver disease among the medical professionals from countries in the MENA region

Article

作者: Nader, Fatema ; Alqahtani, Saleh A. ; Younossi, Zobair M ; Sanai, Faisal M ; Abaakhail, Faisal ; Alghamdi, Saad ; Stepanova, Maria ; Younossi, Zobair M. ; Yilmaz, Yusuf ; Al-Hamoudi, Waleed K. ; Alqahtani, Saleh A ; Alswat, Khalid ; Sanai, Faisal M. ; El-Kassas, Mohamed ; Mawardi, Mohamed ; Al-Hamoudi, Waleed K

INTRODUCTION AND OBJECTIVES:

Given the substantial burden of metabolic dysfunction-associated steatotic liver disease (MASLD), there is an urgent need to assess knowledge and awareness levels among physicians. We assessed MASLD knowledge among healthcare providers from Saudi Arabia, Egypt, and Türkiye.

MATERIALS AND METHODS:

Two global surveys containing 54-59 items assessed awareness and knowledge of MASLD/NAFLD- one was for hepatologists and gastroenterologists, and the second was for non-specialists (e.g. endocrinologists, primary care providers [PCPs], and other healthcare professionals). Data were collected using an electronic data collection form. Knowledge scores and variables associated with higher knowledge scores were compared across all specialties.

RESULTS:

A total of 584 physicians completed the survey (126 hepatologists, 178 gastroenterologists (GEs), 38 endocrinologists, 242 PCPs/others). Practice guidelines were the primary source for knowledge across all specialties (43-51%), then conferences (24-31%) except PCPs/others who selected the internet as the second common source (25%). Adherence to societal guidelines varied by specialty (81-84% of specialists vs 38-51% of non-specialists). Hepatologists and GEs showed similar mean knowledge scores (51-72% correct answers across three knowledge domains, p > 0.05); endocrinologists outperformed PCPs/others in knowledge scores in all knowledge domains, including Epidemiology/Pathogenesis (72% vs. 60%), Diagnostics (73% vs. 67%), and Treatment (78% vs. 67%) (all p < 0.01). Hospital-based practice and seeing a greater number of patients with MASLD/NAFLD were identified as independent predictors of higher knowledge scores among specialists (both p < 0.05).

CONCLUSIONS:

A knowledge gap in the identification, diagnosis, and management of MASLD/NAFLD was found despite the growing burden of MASLD/NAFLD in Saudi Arabia, Egypt, and Türkiye. Education to increase awareness is needed.

2025-01-01·JOURNAL OF ETHNOPHARMACOLOGY

Exploring the therapeutic potential of Pongamia pinnata plant extract against skin cancer: In-silico and in-vitro study

Article

作者: Sayed, Samy ; Jafri, Ibrahim ; Aditi, N ; Rachana, V. ; Raghu, Megha ; Alsharif, Ghadi ; Mushtaq, Muntazir ; Tidke, Shashank A ; Rachana, V ; Prasanna, Akshatha ; Aditi, N. ; Karthik, Yalpi ; Tidke, Shashank A. ; Narayanappa, Rajeswari ; Ramakrishna, D ; Navyatha Karamala, Lakshmi ; Ramakrishna, D.

ETHNOPHARMACOLOGICAL RELEVANCE:

Pongamia pinnata Linn belonging to the Fabaceae family, holds significance as a crucial remedy in herbal medicine.

AIM OF THE STUDY:

The present study aims to determine the anticancer and antioxidant properties of the plant extract.

MATERIAL AND METHODS:

The methodology includes extraction of the leaf sample by soxhlet method followed by the phytochemical analysis of leaf extract. Through in-silico approach three anti-cancer receptors were analyzed with 10 ligands which were studied using molecular docking and molecular simulation approach. The prediction outcome of in-silico tests on the petroleum ether plant extract served as a foundation for the subsequent in-vitro studies. Phytochemical profiling of plant extracts using GC-MS analysis, and cytotoxicity testing for A431 skin cell line using MTT Assay.

RESULTS:

The binding affinity of Pongamia pinnata as an anti-cancer agent with respect to the targets EGF, EGFR, ERBB2 was evident. In the in-silico studies, the highest binding affinity with respect to the docked complexes were -8.2 kcal/mol for EGF with Pazopanib, -8.3 kcal/mol for EGFR with pongachromene, -9.5 kcal/mol for ERBB2 with Vitexin. Further these complexes were assessed by molecular simulations and it confirms the stability of these complexes. In in-vitro studies the HPLC results indicated the presence of 0.176 ± 0.001 mg/mL of phenols and 0.159 ± 0.001 mg/mL of flavonoids. The IC50 value was 1.051 which revealed the antioxidant potential. The cytotoxicity studies against the A431 skin cancer cell resulted in an IC50 concentration of 89.59 μg/ml.

CONCLUSIONS:

These studies show that P. pinnata has the properties to serve as a therapeutic agent for the treatment of skin tumors. The molecular simulation studies approach is a predictor for drug discovery, acting as a basis for testing anti-cancer activity against the skin tumor. As a result, it can be a useful source of crude drug for the treatment of melanomas.

2024-12-31·Journal of medical economics

Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia

Article

作者: Al-Omar, Hussain A ; Almodaimegh, Hind S ; Al-Harbi, Ibtisam ; Hassan, Mohamed ; Alzubaidi, Lamya M ; Akhtar, Omar ; Al-Harbi, Bandar ; Omaer, Abubker

BACKGROUND AND OBJECTIVES:

This study presents a budget impact analysis (BIA) conducted in Saudi Arabia, evaluating the cost implications of adopting semaglutide, tirzepatide, or dulaglutide in the management of type 2 diabetes mellitus (T2DM) patients. The analysis aims to assess the individual budgetary impact of these treatment options on healthcare budgets and provide insights for decision-makers.

METHODS:

A prevalence-based BIA was developed using real-world and clinical trials data. The model considered disease epidemiology, medication prices, diabetes management expenses, cardiovascular (CV) complications costs, and weight reduction savings over a 5-year time horizon. One-way and probabilistic sensitivity analyses (OWSA, PSA) were performed to assess the robustness of the results.

RESULTS:

Over a 5-year period, the cumulative budget impact for semaglutide, tirzepatide, and dulaglutide were 85,923,089 USD, 169,790,195 USD, and 94,558,356 USD, respectively. Hypothetical scenarios considering price parity between semaglutide and tirzepatide are associated with financial impacts of 85,923,091 USD and 86,475,335 USD, respectively. In the public sector, semaglutide showed the lowest incidence of 3-point major adverse CV events (3P-MACE), with tirzepatide leading in weight loss and HbA1c reduction, and dulaglutide presenting the highest 3P-MACE rates and least improvements in HbA1c and weight. A breakeven analysis suggested that tirzepatide's list price would need to be $199.91 lower than its current list price to achieve budget impact parity with semaglutide based on currently available evidence. Results from the OWSA suggested that risk reductions for CV events were key drivers of budget impact. PSA results were confirmatory of base-case analyses.

CONCLUSIONS:

CV cost-offsets and drug acquisition considerations may make semaglutide a favorable use of resources for Saudi budget planners and decision-makers. These results were robust to assumptions regarding the list price of tirzepatide.

项与北京九棵树国际医药技术研究中心大庆分中心相关的新闻（医药）

2024-11-22

·动脉网

Biotech出海扎堆，如何借东风扬帆远航？

在全球医药创新版图上，中国正以前所未有的速度和规模崭露头角。众多企业不仅在国内市场取得了显著成就，更开始将目光投向海外，积极寻求全球合作与市场拓展。 11月12日，国家卫生健康委在京召开医药企业座谈会，鼓励医药企业发挥中外交流的桥梁纽带作用，支持国内企业“走出去”，促进国际交流，合作共赢。作为中东地区最大的医药市场，也是中国在中东地区连续多年的第一大贸易伙伴，沙特丰富的资源、活跃的经济环境以及医疗市场的持续增长，为全球企业提供了广阔的机遇。近两年来持续升温的沙特出海热潮便是对沙特市场潜力最好的印证。面对这片蓝海，中国企业如何突破文化壁垒和营商环境的差异，把握机遇培养第二增长曲线？ 01 借会出海，“丝路繁花”释放中国医疗创新力量 2024年1月1日，沙特成为金砖国家正式成员。“一带一路”+“金砖”，叠加的buff背后是中沙两国愈加紧密的交流合作以及多领域的合作潜力。 2016年，沙特阿拉伯提出“沙特2030愿景”，旨在摆脱石油依赖，实现经济多元化，并明确将医疗健康作为国家发展的核心领域。对于希望实现生物技术产业链本土化的沙特，中国医疗企业是其热切想要吸引的伙伴。 11月10日至12日，2024第三届利雅得全球医学生物技术峰会（RGMBS）在沙特首都利雅得成功召开。作为沙特最高规格的政府活动平台之一，RGMBS旨在推动国际交流合作，引入优质产业资源，推动沙特成为全球生物技术创新中心。在此次RGMBS上，“中国创新”无疑是一个关键词。作为本届峰会的重要合作伙伴，阿斯利康携手中国医药创新促进会（药促会）联合组织出海交流活动，携近70家中国企业、行业协会、科研机构、高校、基金等赴沙特参会、参展，刷新了RGMBS史上中国企业和机构参会的最大规模纪录。中国企业与机构在论坛发言、合作签约、路演及展台悉数亮相，贡献了诸多高光时刻。先声药业、华大基因、迪英加、中金资本等企业和机构作为嘉宾出席多场分论坛发言，分享中国创新故事。威斯津、安序源、珞珈云脉、帝迈等企业在“Demo Day路演”环节，面对70多家沙特投资机构展示创新成果。同时，基于医疗创新与商业落地的合作也在不断涌现。零氪科技、西比曼生物、迪英加科技分别与沙特阿卜杜拉国王医学研究中心（KAIMRC）和沙特国民警卫队卫生事务部（MNGHA）签署了战略合作协议。此外，本届峰会还为中国企业在中心展区设立专属展位，以展促产助力中国创新“出海”，落地中东。智众医疗、百鸿、海尔医疗、至善唯新、星亢原、睿笛生物、威斯津、轻盈医疗这8家中国企业参展，与来自全球的潜在合作伙伴接洽合作意向。借会出海、以展促产，正成为中国试水新市场的最优解。 02 构建桥梁，链动全球助力中国惠及全球从产业发展的视角来看，中国生物医药出海需要对当地市场需求、政策、供应链、渠道、投资等方方面面有深度理解。多方力量“抱团取暖”，才能构建可持续的出海链条，共享市场红利。而深耕中国三十多年的阿斯利康，正在构建国际化交流的桥梁，推动中国创新企业和创新成果“走出去”。 RGMBS期间，在阿斯利康和药促会的支持下，零氪科技、广州实验室等30多家中国企业和机构进行实地考察走访，与沙特政、产、学、研、医、投核心资源对接。企业团一行分别与来自沙特阿卜杜拉国王医学研究中心(KAIMRC)、沙特德•本•阿卜杜拉齐兹国王健康科学大学(KSAU-HS)、法赫德国王国民警卫队医院(King Fahad National Guard Hospital)、沙特本地化和政府采购管理局（LCGPA）、沙特食品药品监督管理局（SFDA）、沙特制药工业和医疗器械公司（SPIMACO）等政府机构和当地企业的代表会面，探索沙特当地医疗市场的实际需求，就医疗领域的合作机遇进行深度探讨。这不仅有助于提升中国医疗创新企业在全球医疗健康产业链中的地位，更将为构建中沙互利共赢的国际医疗贸易合作注入新动能。在此之前，借助阿斯利康的全球网络，130多家中国生物医药创新企业成功出海巴西、中东等新兴市场，10余家中国企业已在全球多个市场落地或达成合作意向。不局限于人口众多、经济发展势头良好的新兴市场，阿斯利康也在积极布局英国、日本等发达市场，将当地的研发创新资源与中国企业的产业化能力紧密结合，扩容国际健康创新生态圈。阿斯利康的在华角色，已不局限于创新药的引进者，还是帮助中国医疗创新“走出去”的同行者。 03 联动政产学研医投，多维孵化中国创新 “赋能”是阿斯利康助力中国创新本土和国际化发展的关键词。 2017年起，阿斯利康携手政、产、学、研、医、投跨界合作伙伴，打造了包括中国智慧健康创新中心（CCiC）、国际生命科学创新园（iCampus），和阿斯利康中金医疗产业基金在内的创新“三架马车”，开放融合，积极促进大健康产业生态圈的广泛交流合作与创新发展。 2019年，国内首个iCampus在无锡开园运营，正式开启阿斯利康与政府携手赋能产业创新的模式。iCampus结合各地产业优势、技术优势，面向创新企业打造覆盖生命科学领域早期研发、创新孵化、成果转化、智能展示、专业服务为一体的孵化创新平台。 5年间，iCampus依托在无锡、北京、上海、杭州、成都、广州、青岛、香港、宜兴9个核心城市完成布点，形成多地协同的生命科学创新生态网络，累计入驻企业超170家，其中不乏有上市企业、准上市企业和独角兽企业，助力打造区域产业创新集群。同时，iCampus在平台模式上也更多元化，搭建一站式成果转化平台，链接园区企业与临床创新技术，促进临床科研成果转化；携手政府打造iCampus基金，通过“基金+园区”模式，以资本赋能创新企业发展；与专家、院士开展产学研合作，建立代谢诊疗一体化产业园MCampus、乳腺诊疗一体化产业园BCampus，形成“临床+产业”双轮驱动的创新模式，来构建垂直疾病领域产业集群，最终惠及更广泛的患者。今年5月，阿斯利康与沙特KAIMRC共同发布中沙医疗健康合作，推动iCampus模式在沙特的落地，将中国的成熟经验带给沙特的同时，为中国企业开辟通向中东市场的快速通道。当出海已经成为时代必答题，阿斯利康以科学与创新为核心，多层次多维度构筑出海桥梁，成为中国创新扬帆远航的“东风”。在全球健康未来的道路上，中国医疗创新企业也正以更开放的姿态、更坚定的步伐，引领全球医药产业的变革与进步。 *封面图片来源：123rf 如果您想对接文章中提到的项目，或您的项目想被动脉网报道，或者发布融资新闻，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台

引进/卖出医药出海

2024-11-15

·Endpoints

Vitalli ends work on Daewoong asset; Alector’s $50M loan

Plus, news about Bavarian Nordic, Nuvectis Pharma, Flashpoint Therapeutics, Sparian Biosciences and TFF Pharmaceuticals: Vitalli Bio axes Daewoong asset: Vitalli, founded by Joe Jimenez’s Aditum Bio , plans to terminate its licensing agreement for an autoimmune disease drug developed by Daewoong Pharmaceutical, according to a regulatory filing . The deal was worth up to $477 million for Daewoong. Vitalli still has the option for two additional candidates from Daewoong, the company said. Jimenez declined to comment, citing “confidentiality with our partners.” — Kyle LaHucik Alector takes out $50M loan: The money from Hercules Capital will help fund two studies: a Phase 3 for latozinemab in frontotemporal dementia, and a Phase 2 for AL002 in early Alzheimer’s disease. Alector will receive $10 million immediately and can get another $15 million at any time before June 30, 2026. The final $25 million will be available at Hercules’ approval. — Max Gelman Bavarian Nordic secures $340M in mpox, smallpox vaccine orders for 2025: The company told investors that the additional mpox orders contributed to its decision to upgrade its financial guidance for this year. Nearly three million doses of the company’s mpox vaccine MVA-BN have been pledged to Africa so far. — Anna Brown Nuvectis Pharma’s stock dives on Phase 1b data: Of 11 evaluable patients with late-line ovarian cancer who took NXP800, a GCN2 kinase activator, only one patient achieved an unconfirmed partial response, the company said . Nuvectis tested multiple dosing regimens, including different amounts and once- or twice-a-day. Nuvectis’ stock $NVCT closed 46% lower on Thursday. — Max Gelman Flashpoint Therapeutics partners with Saudi Arabia, Northwestern University: The biotech is teaming up with the King Abdullah International Medical Research Center in Riyadh in a $50 million effort to establish a new nanomedicine research center, which will receive the money over five years. Flashpoint also said it expanded its IP to include “150 issued patents and patent applications” through a deal with Northwestern. — Max Gelman Sparian Biosciences’ $19.5M NIH grant: The New York biotech got a five-year grant from the National Institute on Drug Abuse to help develop an opiate use disorder drug through Phase 1. It got a similar grant last year for another drug that aims to treat stimulant use disorder. — Kyle LaHucik TFF Pharmaceuticals to wind down: The Fort Worth, TX-based biotech let go all employees and will shut down . It had been working on dry powder formulations for drugs, including for lung transplant rejection, flu and Covid. It had $4.4 million in cash and equivalents at the end of June. — Kyle LaHucik

疫苗引进/卖出临床2期临床1期

2023-07-03

·PRNewswire

AAHRPP Awards Accreditation to King Abdullah International Medical Research Center (KAIMRC)

WASHINGTON, July 3, 2023 /PRNewswire/ -- The Association for the Accreditation of Human Research Protection Programs has accredited King Abdullah International Medical Research Center (KAIMRC), a leading research center with physical presence in Riyadh, Jeddah, and Al-Aḥsa, Saudi Arabia. KAIMRC is the third organization in Saudi Arabia to achieve AAHRPP accreditation. "Protecting research participants is a worldwide goal, one which AAHRPP accreditation recognizes. In achieving AAHRPP accreditation, KAIMRC has demonstrated its dedication to this important objective," AAHRPP President and CEO Elyse I. Summers said. "With each accreditation, we are adding to our global network of organizations that share a commitment to high-quality, ethical research." AAHRPP has accredited more than 600 research entities across the U.S. and in Australia, Belgium, Brazil, Canada, China, India, Japan, Jordan, Mexico, Republic of Korea, Saudi Arabia, Singapore, Taiwan, and Thailand. All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, more than 85% of the top U.S. National Institutes of Health-funded academic medical centers and 70% of U.S. medical colleges are AAHRPP-accredited or have begun the accreditation process. Research institutes, clinical research centers, and community hospitals also are among those that have attained accreditation. About AAHRPP: A nonprofit organization, AAHRPP provides accreditation for organizations that conduct or review human research and can demonstrate that their protections exceed the safeguards required by the international guidelines and laws governing research involving humans in the U.S. and other countries. To learn more, visit . FOR MORE INFORMATION CONTACT: Michelle Feige Executive Vice President [email protected] 202-783-1112 SOURCE Association for the Accreditation of Human Research Protection Programs

临床研究

100 项与北京九棵树国际医药技术研究中心大庆分中心相关的药物交易

登录后查看更多信息

100 项与北京九棵树国际医药技术研究中心大庆分中心相关的转化医学

登录后查看更多信息